Disclaimer: Not an advise. Informational and Educational use only.<\/p>\n\n\n\n
Standard of care: ACNS0423 Study Brain Tumor IND: ACT001 : How it works Brain Tumor IND: ACT001 : Safety:<\/strong><\/p>\n\n\n\n Brain Tumor IND: ACT001: Efficacy (signals, early):<\/strong><\/p>\n\n\n\n Brain Tumor IND: ACT001: Existing Trials:<\/strong> Other existing IND trials and hospital informations:<\/p>\n\n\n\n https:\/\/connectconsortium.org\/clinical-trials\/<\/a><\/p>\n\n\n\n https:\/\/clinicaltrials.gov\/search?cond=gbm<\/a> Disclaimer: Not an advise. Informational and Educational use only. Standard of care: ACNS0423 StudyIntroduction: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5035517\/Reports outcomes (EFS\/OS) and toxicity profile, including the central conclusion that this regimen had acceptable but meaningful hematologic toxicity and only modest improvement vs historical expectations. Disclaimer: Not advocating for any specific drugs. Informational and educational purposes only for may be … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"slim_seo":{"title":"Information on Cancers and Brain Tumors including current INDs (draft) - FYI: IND Access Information","description":"Disclaimer: Not an advise. Informational and Educational use only. Standard of care: ACNS0423 Study Introduction: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC50355"},"footnotes":""},"class_list":["post-21","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/pages\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indaccess.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21"}],"version-history":[{"count":7,"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/pages\/21\/revisions"}],"predecessor-version":[{"id":44,"href":"https:\/\/indaccess.org\/index.php?rest_route=\/wp\/v2\/pages\/21\/revisions\/44"}],"wp:attachment":[{"href":"https:\/\/indaccess.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Introduction: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5035517\/
Reports outcomes (EFS\/OS) and toxicity profile, including the central conclusion that this regimen had acceptable but meaningful hematologic toxicity<\/strong> and only modest improvement<\/strong> vs historical expectations. <\/a>
Disclaimer: Not advocating for any specific drugs. Informational and educational purposes only for may be used to apply for SPIND only. May add more drugs. <\/p>\n\n\n\n
Mechanism in glioblastoma models: targets STAT3 \u2192 lowers PD-L1 transcription \/ immunosuppression<\/strong> (preclinical + mechanistic). PMC<\/a>
Additional glioma mechanism work: targets glioma stem-like cells<\/strong> and anti-tumor effects in GBM models (mechanistic preclinical). PMC<\/a><\/p>\n\n\n\n\n
\n
NCT05053880<\/strong> \u2014 ACT001 + anti-PD-1<\/strong> in surgically accessible recurrent GBM<\/strong>.
NCT06838676<\/strong> \u2014 Phase II ACT001 in children\/adolescents with DIPG and H3K27-altered HGG<\/strong> (CONNECT2110). ClinicalTrials+1<\/a>
<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"